IDEAYA Biosciences, Inc. (IDYA) News
Filter IDYA News Items
IDYA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IDYA News Highlights
- IDYA's 30 day story count now stands at 2.
- Over the past 3 days, the trend for IDYA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest IDYA News From Around the Web
Below are the latest news stories about IDEAYA BIOSCIENCES INC that investors may wish to consider to help them evaluate IDYA as an investment opportunity.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on November 30, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 40,000 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan ( |
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations EventIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations event. |
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder CancerIDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical study collaboration and supply agreement with Gilead Sciences, Inc. (Gilead) to evaluate the efficacy and safety of IDE397, its investigational, potential first-in-class, small molecule MAT2A inhibitor, in combination with Gilead's sacituzumab-govitecan-hziy ("Trodelvy"), a Trop-2 directed antibody-drug conjuga |
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 4, 2023 at 8:00 am to 9:30 am ET. |
Can IDEAYA Biosciences, Inc. (IDYA) Climb 25.48% to Reach the Level Wall Street Analysts Expect?The mean of analysts' price targets for IDEAYA Biosciences, Inc. (IDYA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Analysts' Revenue Estimates For IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Are Surging HigherIDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders will have a reason to smile today, with the analysts making... |
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue EstimatesIDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 2.13% and 22.98%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
IDEAYA Biosciences Inc (IDYA) Reports Q3 2023 Financial Results and Business UpdateStrong balance sheet and robust clinical pipeline highlight the company's Q3 performance |
IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business UpdateIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2023. |
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare ConferenceIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2023. |